Mona Shing
About
Mona Shing is a scholar working on Oncology, Cancer Research and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Mona Shing has authored 29 papers receiving a total of 913 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 15 papers in Cancer Research and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mona Shing's work include HER2/EGFR in Cancer Research (17 papers), Breast Cancer Treatment Studies (10 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Mona Shing is often cited by papers focused on HER2/EGFR in Cancer Research (17 papers), Breast Cancer Treatment Studies (10 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Mona Shing collaborates with scholars based in United States, Germany and Switzerland. Mona Shing's co-authors include Marianne Ulcickas Yood, Debu Tripathy, Denise A. Yardley, Lisa I. Wang, Adam Brufsky, Musa Mayer, Elizabeth Tan-Chiu, Melissa Brammer, Iulia Cristina Tudor and Hope S. Rugo and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.
In The Last Decade
Mona Shing
28 papers receiving 898 citations
Peers
Mona Shing
David P. Kodack United States
Maria Hersom Denmark
Tsukasa Sakaida Japan
Mario Caccese Italy
Ziren Kong China
Jacob Ruzevick United States
Yonggao Mou China
Shannon Matheny United States
Yong Cui China
Eleazar Vega-Valle United States
Citations per year, relative to Mona Shing Mona Shing (= 1×)
peers
David P. Kodack
Countries citing papers authored by Mona Shing
Since
Specialization
Citations
This map shows the geographic impact of Mona Shing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mona Shing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mona Shing more than expected).
Fields of papers citing papers by Mona Shing
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mona Shing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mona Shing. The network helps show where Mona Shing may publish in the future.
Co-authorship network of co-authors of Mona Shing
This figure shows the co-authorship network connecting the top 25 collaborators of Mona Shing. A scholar is included among the top collaborators of Mona Shing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mona Shing. Mona Shing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Müller, Volkmar, Michael Clemens, Jacek Jassem, et al.. (2018). Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer. BMC Cancer. 18(1). 295–295.
2.
Lidbrink, Elisabet, Ewa Chmielowska, Burkhard Otremba, et al.. (2018). A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study. Breast Cancer Research and Treatment. 174(1). 187–196.
3.
Lidbrink, Elisabet, J. Erfán, Ewa Chmielowska, et al.. (2017). OHERA: A real world study of cardiac events in > 3700 patients with her2-positive early breast cancer treated with trastuzumab: Final analysis. Annals of Oncology. 28. v52–v52.
4.
Shah, Manish A., Rui‐Hua Xu, Yung‐Jue Bang, et al.. (2017). HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology. 35(22). 2558–2567.
5.
Jung, Kyung Hae, Beyhan Ataseven, Mark Verrill, et al.. (2016). Adjuvant subcutaneous trastuzumab for HER2-positive early breast cancer: Phase III SafeHer study subgroup analyses of body weights, active medical conditions, safety and tolerability. Annals of Oncology. 27. vi63–vi63.
6.
Jackisch, Christian, Roberto Hegg, Daniil Stroyakovskiy, et al.. (2016). HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up. European Journal of Cancer. 62. 62–75.
7.
Ahn, Jin Seok, Christian Jackisch, Roberto Hegg, et al.. (2015). 55O_PR Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival by body weight and anti-drug antibody status. Annals of Oncology. 26. ix16–ix16.
8.
Gligorov, Joseph, Michelino De Laurentiis, Mark Verrill, et al.. (2015). P103 Subcutaneous trastuzumab plus chemotherapy for early breast cancer: interim safety from SafeHer. The Breast. 24. S60–S61.
9.
Koehler, Niklas, Elke Stransky, Susanne Gaertner, et al.. (2015). Alpha-Synuclein Levels in Blood Plasma Decline with Healthy Aging. PLoS ONE. 10(4). e0123444–e0123444.
10.
Jackisch, Christian, Roberto Hegg, Daniil Stroyakovskiy, et al.. (2015). P201 Subcutaneous versus intravenous trastuzumab in early breast cancer: 2-year follow-up of HannaH. The Breast. 24. S94–S94.
11.
Jackisch, Christian, Roberto Hegg, Daniil Stroyakovskiy, et al.. (2015). Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC).. Journal of Clinical Oncology. 33(15_suppl). 585–585.
12.
Koehler, Niklas, Elke Stransky, Mona Shing, et al.. (2013). Altered Serum IgG Levels to α-Synuclein in Dementia with Lewy Bodies and Alzheimer’s Disease. PLoS ONE. 8(5). e64649–e64649.
13.
Perez, Edith A., Michael F. Press, Amylou C. Dueck, et al.. (2013). Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Research and Treatment. 138(1). 99–108.
14.
Drappatz, Jan, Andrew Brenner, Eric T. Wong, et al.. (2013). Phase I Study of GRN1005 in Recurrent Malignant Glioma. Clinical Cancer Research. 19(6). 1567–1576.
15.
Brufsky, Adam, Musa Mayer, Hope S. Rugo, et al.. (2011). Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER. Clinical Cancer Research. 17(14). 4834–4843.
16.
Wen, Patrick Y., Jan Drappatz, Andrew Brenner, et al.. (2011). Abstract B49: GRN1005 phase I studies: Final results.. Molecular Cancer Therapeutics. 10(11_Supplement). B49–B49.
17.
Gruschkus, Stephen K., et al.. (2010). First-line patterns of care and outcomes of HER2-positive breast cancer patients who progressed after receiving adjuvant trastuzumab in the outpatient community setting.. Journal of Clinical Oncology. 28(15_suppl). 684–684.
18.
Mitchell, Edith P., et al.. (2009). Panitumumab Monotherapy in Patients with Metastatic Colorectal Cancer and Cetuximab Infusion Reactions: A Series of Four Case Reports. Clinical Colorectal Cancer. 8(1). 49–54.
19.
Koehler, Niklas, Matthias Ballmaier, Peter Claus, et al.. (2007). Up‐regulation of platelet‐derived growth factor by peripheral‐blood leukocytes during experimental allergic encephalomyelitis. Journal of Neuroscience Research. 86(2). 392–402.
20.
Shing, Mona & David Rubenson. (2001). Embolic stroke and cardiac papillary fibroelastoma. Clinical Cardiology. 24(4). 346–347.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by David P. Kodack Breakdown of academic impact, for papers by Maria Hersom Breakdown of academic impact, for papers by Tsukasa Sakaida Breakdown of academic impact, for papers by Mario Caccese Breakdown of academic impact, for papers by Ziren Kong Breakdown of academic impact, for papers by Jacob Ruzevick Breakdown of academic impact, for papers by Yonggao Mou Breakdown of academic impact, for papers by Shannon Matheny Breakdown of academic impact, for papers by Yong Cui Breakdown of academic impact, for papers by Eleazar Vega-Valle